信達生物製藥

INNOVENT BIOLOGICS, INC.

(Incorporated in the Cayman Islands with Limited Liability)

(Stock Code: 1801)

CLOSING OF GLOBAL STRATEGIC PARTNERSHIP WITH TAKEDA AND ISSUANCE OF SHARES UNDER GENERAL MANDATE

Reference is made to the announcement of the Company dated October 22, 2025 (the "**Announcement**"). Unless defined otherwise, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

The Board of Directors is pleased to announce that all conditions precedent to each of the License, Option and Collaboration Agreement and the Share Issuance Agreement have been fulfilled or waived (where applicable). Accordingly, closing of the License, Option and Collaboration Agreement has taken place and the closing of the Share Issuance Agreement took place on December 4, 2025.

Upon the closing of the Share Issuance Agreement, 6,913,834 Shares were allotted and issued by the Company to the Subscriber, representing approximately 0.40% of the issued share capital of the Company after issuance of the Subscription Shares. The gross proceeds from the allotment and issuance of the Subscription Shares was approximately HK$778 million (based on the subscription price of HK$112.56 per Subscription Share), and the net proceeds, after deduction of all relevant expenses incidental to the allotment and issue of the Subscription Shares, was approximately HK$777 million. For further details on the use of proceeds, please refer to the Announcement.

The Subscription Shares were issued under the General Mandate. The General Mandate entitles the Board of Directors to issue, allot and deal with up to 248,010,358 Shares, representing 15% of the issued share capital of the Company as of June 25, 2025. Immediately prior to the Subscription, 193,010,358 Shares representing approximately 11.26% of the issued share capital of the Company were available for issuance under the General Mandate. Following the closing, the Company may allot, issue and deal with up to 186,096,524 Shares pursuant to the General Mandate.

By Order of the Board
Innovent Biologics, Inc.
Dr. De-Chao Michael Yu
Chairman and Executive Director

Hong Kong, China,
December 5, 2025

As at the date of this announcement, the Board comprises Dr. De-Chao Michael Yu as Chairman and executive Director and Mr. Ronald Hao Xi Ede and Ms. Qian Zhang as executive Directors, and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Mr. Gary Zieziula, Dr. Shun Lu, Mr. Shuyun Chen and Dr. Stephen A. Sherwin as independent non-executive Directors.